Indaptus Therapeutics, Inc.
INDPIndaptus Therapeutics is a clinical-stage biotechnology company developing a novel systemically-administered immunotherapy platform for the treatment of cancer and viral infections.
Table of contents
Earnings
Next report
Aug 17, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Indaptus Therapeutics is a clinical-stage biotechnology company developing a novel systemically-administered immunotherapy platform for the treatment of cancer and viral infections. The company's technology utilizes attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate both innate and adaptive immune responses while minimizing toxicity. Their lead candidate, Decoy20, is engineered to prime the immune system to recognize and destroy tumors without requiring the provision of specific tumor antigens.
Indaptus is a pioneer in the systemic administration of killed bacteria for immunotherapy, leveraging a patented approach to reduce LPS-endotoxin toxicity while maintaining immune-priming efficacy.
Questions, answered.
- What is Indaptus Therapeutics, Inc.'s market cap?
- Indaptus Therapeutics, Inc. (INDP) has a market capitalization of $333.1M and trades on NASDAQ.
- Who are Indaptus Therapeutics, Inc.'s competitors?
- Indaptus Therapeutics, Inc.'s key competitors include Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Indaptus Therapeutics, Inc. partner with?
- Indaptus Therapeutics, Inc.'s notable partners include BeOne Medicines, H.C. Wainwright & Co. LLC, Paulson Investment Company, LLC.
- Where is Indaptus Therapeutics, Inc. headquartered?
- Indaptus Therapeutics, Inc. is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2021.